These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20624773)

  • 21. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy.
    Tokura T; Itano S; Kobayashi S; Kuwabara A; Fujimoto S; Horike H; Satoh M; Komai N; Tomita N; Matsunaga A; Saito T; Sasaki T; Kashihara N
    J Atheroscler Thromb; 2011; 18(6):536-41. PubMed ID: 21467726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy.
    Saito T; Ishigaki Y; Oikawa S; Yamamoto TT
    Trends Cardiovasc Med; 2002 Feb; 12(2):67-70. PubMed ID: 11852253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel apolipoprotein E mutation caused by a five amino acid deletion in a Chinese family with lipoprotein glomerulopathy: a case report.
    Xie W; Xie Y; Lin Z; Xu X; Zhang Y
    Diagn Pathol; 2019 May; 14(1):41. PubMed ID: 31092271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity.
    Sakatsume M; Kadomura M; Sakata I; Imai N; Kondo D; Osawa Y; Shimada H; Ueno M; Miida T; Nishi S; Arakawa M; Gejyo F
    Kidney Int; 2001 May; 59(5):1911-8. PubMed ID: 11318963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America.
    da Silveira-Neto JN; de Oliveira Ahn GJ; de Menezes Neves PDM; Baptista VAF; de Almeida Araújo S; Wanderley DC; Watanabe A; Watanabe EH; Murai NM; Bertollo EMG; Vieira-Neto OM; Dantas M; de Antônio SR; Costa RS; Baptista MASF; Moysés-Neto M; Onuchic LF
    Diagn Pathol; 2021 Jul; 16(1):65. PubMed ID: 34311745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A rare cause of nephrotic syndrome: lipoprotein glomerulopathy.
    Cheung CY; Chan AO; Chan YH; Lee KC; Chan GP; Lau GT; Shek CC; Chau KF; Li CS
    Hong Kong Med J; 2009 Feb; 15(1):57-60. PubMed ID: 19197098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apolipoprotein E-related glomerular disorders.
    Saito T; Matsunaga A; Fukunaga M; Nagahama K; Hara S; Muso E
    Kidney Int; 2020 Feb; 97(2):279-288. PubMed ID: 31874799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topics in lipoprotein glomerulopathy: an overview.
    Saito T; Matsunaga A; Ito K; Nakashima H
    Clin Exp Nephrol; 2014 Apr; 18(2):214-7. PubMed ID: 24149835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.
    Stratikos E; Chroni A
    Clin Exp Nephrol; 2014 Apr; 18(2):225-9. PubMed ID: 24149834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town.
    Pasquariello A; Pasquariello G; Innocenti M; Minnei F; Funel N; Lorusso P; Barsotti G
    J Nephrol; 2011; 24(3):381-5. PubMed ID: 21534236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipoprotein glomerulopathy: clinical features and pathological characteristics in Chinese.
    Chen HP; Liu ZH; Gong RJ; Tang Z; Zeng CH; Zhu MY; Wang JP; Zhou H; Li LS
    Chin Med J (Engl); 2004 Oct; 117(10):1513-7. PubMed ID: 15498375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
    Arai T; Yamashita S; Yamane M; Manabe N; Matsuzaki T; Kiriyama K; Kanayama Y; Himeno S; Matsuzawa Y
    Atherosclerosis; 2003 Aug; 169(2):293-9. PubMed ID: 12921981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features.
    Saito T; Oikawa S; Sato H; Sato T; Ito S; Sasaki J
    Kidney Int Suppl; 1999 Jul; 71():S37-41. PubMed ID: 10412734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.
    Luo B; Huang F; Liu Q; Li X; Chen W; Zhou SF; Yu X
    Am J Nephrol; 2008; 28(2):347-53. PubMed ID: 18046082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoprotein glomerulopathy in China.
    Chen Y
    Clin Exp Nephrol; 2014 Apr; 18(2):218-9. PubMed ID: 24165683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New evolution in lipoprotein glomerulopathy].
    Saito T; Matsunaga A; Nakashima H
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1314-9. PubMed ID: 24288968
    [No Abstract]   [Full Text] [Related]  

  • 37. Signaling pathways of apoE and its role of gene expression in glomerulus diseases.
    Zhou TB
    J Recept Signal Transduct Res; 2013 Apr; 33(2):73-8. PubMed ID: 23384034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy.
    Oikawa S; Matsunaga A; Saito T; Sato H; Seki T; Hoshi K; Hayasaka K; Kotake H; Midorikawa H; Sekikawa A; Hara S; Abe K; Toyota T; Jingami H; Nakamura H; Sasaki J
    J Am Soc Nephrol; 1997 May; 8(5):820-3. PubMed ID: 9176854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Physiopathology of lipoprotein glomerulopathy].
    Saito T
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1838-44. PubMed ID: 17037324
    [No Abstract]   [Full Text] [Related]  

  • 40. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.
    Ishimura A; Watanabe M; Nakashima H; Ito K; Miyake K; Mochizuki S; Ishigaki Y; Saito T
    Clin Exp Nephrol; 2009 Oct; 13(5):430-437. PubMed ID: 19459027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.